Kevin Carlisle, MD
Family Medicine · Rayville, LANPI 1326337635
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,543 of the $18,087 with a category attached, or 85.9%. It is spread thinly across 55 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 900 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$4K
- Amgen$2K
- AbbVie$2K
- Johnson & Johnson$1K
- AstraZeneca$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$883
- plus $7K from 49 others
What the payments were for
- Speaking & faculty fees$2,50014%
- Food & beverage$15,54386%
- Education$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,087 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 207 | $231,767 |
| EliquisApixaban | 283 | $137,047 |
| OzempicSemaglutide | 118 | $122,079 |
| JardianceEmpagliflozin | 103 | $116,701 |
| FarxigaDapagliflozin Propanediol | 134 | $100,612 |
| EntrestoSacubitril/Valsartan | 137 | $97,817 |
| XareltoRivaroxaban | 188 | $92,098 |
| LinzessLinaclotide | 101 | $81,814 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 104 | $80,606 |
| VraylarCariprazine Hcl | 80 | $76,388 |
| MyrbetriqMirabegron | 177 | $73,554 |
| NuedextaDextromethorphan Hbr/Quinidine | 81 | $63,385 |
| RexultiBrexpiprazole | 70 | $60,516 |
| TrulicityDulaglutide | 35 | $46,742 |
| IngrezzaValbenazine Tosylate | 11 | $42,857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $222 | $278,509242 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr, Tradjenta | $312 | $186,045229 claims |
| AbbVieLinzess, Vraylar, Creon | $2,060 | $178,256198 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $1,346 | $158,349252 claims |
| PfizerEliquis | $3,525 | $137,047283 claims |
| Novo NordiskOzempic | $443 | $122,079118 claims |
| Johnson & JohnsonXarelto, Invokana | $1,376 | $101,197206 claims |
| NovartisEntresto | $121 | $97,817137 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $683 | $94,108124 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $180 | $79,642188 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Relistor | $883 | $71,08664 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $150 | $63,38581 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Rayville
- Matthew PrineRayville$15K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
- Phillip ConnerSulphur$71K
- Richard JeansonneMandeville$49K
- Leonard TreanorHammond$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.